Hello, my name is Angela Dispensieri. I'm from the Mayo Clinic, Rochester, Minnesota, and I'm here in Brazil at IMS 2024. It's been a great meeting with a lot of new information and some sort of review of some old information. Where to start? I think one of the most important things that's going to be very easy to put into practice is the new definition for high-risk myeloma. And so that's a definite advance trying to really get us all talking in the same language about what defines high-risk myeloma. And so that's an improvement and something that will be published soon. The other really interesting thing was the session today on both CAR T and other types of cellular therapies and by specific T cell engagers. And again, we all know the benefits so far of single agent anti-BCMA like to Toclistomab and Elrantamab. And we know about Telketomab as the by specific engagers and we know now more about using combinations. So there was some really amazing data presented about the combination of Toclistomab and Telketomab, showing very promising response rates and complete response rates in patients that have had a lot of prior therapies. There's the combination of Daratumumab with pomalidomide and Telketomab. There was information on how to sequence these different antibodies and also CAR T. And so that has been a challenge for all of us and we're not there yet in completely understanding these data, but there's some amazing new innovations in terms of potentially new products and new ways to influence to make a patient's immune system more receptive to these different therapies. So that was really exciting. There also was more information about using quadruplet therapy, things like either Daratumumab or Isotuximab along with Bortezomib, Lenalidomide and DEX. And again, we've known for years now that this is very effective therapy based on the Perseus trial with response rates, nearly 100% of patients, etc. But the newer bit is that quadruplet therapy is also potentially a good option in elderly patients, so non-transplant patients. Now we don't have overall survival data for most of that, so we're more to learn and I think we need to be a little bit cautious amongst the very elderly patients getting quads because these trials limited people up to the age of 80 and we know they're myeloma patients that are older than that. So triplets are still really good and so that's very, very important.